MSLN and ovarian carcinoma: Additionally, pre-treatment of MSLN + ovarian cancer cell line (OVCAR-3) with LatA prior co-culture to mesoCAR T cells containing CD28 or 4-1BB costimulatory domains resulted in a 50% reduction in the frequency of MSLN + mesoCAR T cells, indicating the actin remodeling-dependent trogocytosis contributes to transfer of MSLN from target tumor cells to mesoCAR T cells [14].